Pharma CEOs: What Should They Say?
Executive Summary
On the eve of the Big Hearing, communication and business strategists offer advice on how to get the grilling to go as well as possible.
You may also be interested in...
HHS Rebate Plan A Leap Of Faith? Lower Costs Hinge On Drug Firm, Plan Response
HHS seeks input on how stakeholders might adjust to a system without rebates and requests comments on three actuarial reports that attempt to project the financial impact of the change.
Insulin Prices, Cancer Treatment Innovation Pushed In State Of The Union As Biden Faces Divided Congress
Expanded federal research efforts around cancer treatment was one of a handful of bipartisan goals that President Biden highlighted in his State of the Union address.
Pink Sheet Podcast: US FDA Loses Gene Therapy Expert, Humira Biosimilars Launch, FDA Allows In-Person Meetings
Pink Sheet reporters and editors consider the impact of FDA Office of Tissues and Advanced Therapies Director Wilson Bryan’s retirement, the launch of Humira biosimilars and its effect on the biologic market, as well as the FDA moving to hybrid meetings with sponsors.